Approval · Notice of Compliance 27778 · 2022
SKYRIZI: Notice of Compliance 27778
Issued March 16, 2022
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 27778
- Date
- March 16, 2022
- Company
- AbbVie CorporationSaint-Laurent, Quebec, Canada
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- New Indication : Psoriatic Arthritis SKYRIZI (risankizumab injection) is indicated for: the treatment of adult patients with active psoriatic arthritis. Skyrizi can be used alone or in combination with a conventional non-biologic diseasemodifying antirheumatic drug (cDMARD) (e.g., methotrexate)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| SKYRIZI | Not yet assigned | — |
Medicinal ingredients
- RISANKIZUMAB 90 MG per ML
- RISANKIZUMAB 150 MG per ML